We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Finalizes Guidance on Developing Drugs to Treat Severe Hematologic Disorders
FDA Finalizes Guidance on Developing Drugs to Treat Severe Hematologic Disorders
The FDA issued final guidance for developers of drugs to treat severely debilitating or life-threatening hematologic disorders (SDLTHDs), such as hemophilia and sickle cell disease.